The table below shows BridgeBio Pharma, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$445.91M
-$520.73M
-$527.72M
-$419.49M
-$497.93M
-$399.71M
Capital expenditure
$1.10M
$933.00K
$1.31M
$4.82M
$13.25M
$7.52M
Investing cash flow
-$24.49M
$60.78M
$54.03M
$453.15M
-$200.83M
-$52.99M
Dividends paid
-
-
-
-
-
BBIO operating cash flow (10-K history)
BridgeBio Pharma, Inc. reported operating cash flow of -$445.91M for fiscal year 2025. That is up 14.4% from -$520.73M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$40.49M (FY 2017) to -$445.91M. Figures come from the company's audited annual reports as filed with the SEC.
